{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:05Z","timestamp":1787785565552,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Axial spondyloarthritis including ankylosing spondylitis (AS) is characterized by chronic inflammation and new bone formation in the axial skeleton. On the other hand, bone loss, osteoporosis and an increased risk of vertebral fractures is known to frequently occur in AS. In the MEASURE 1 study, the clinically efficacious interleukin-17A inhibitor secukinumab was shown to have limited radiographic progression through 4\u2009years in patients with active AS. Here we present a post hoc analysis to evaluate the effect of secukinumab on bone mineral density (BMD) and bone turnover biomarkers over 2\u2009years in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>BMD was measured by dual-energy X-ray absorptiometry at the lumbar spine, total hip, and femoral neck. Spinal radiographs performed at baseline and Week 104 were assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and analyzed in relation to BMD change, considering baseline syndesmophytes. Bone turnover biomarkers were assessed at baseline and at Weeks 52 or 104.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 104 patients included in this analysis, 66% were male, with a mean (SD) age of 40.4 (12.3) years. In postmenopausal women and men \u226550\u2009years of age (T-score), the proportion of patients having normal BMD at baseline and Week 104 were 54.5%\/54.5% (lumbar spine), 31.6%\/55.6% (total hip), and 42.1%\/44.4% (femoral neck). Similarly, at baseline, the proportion of patients with osteopenia\/osteoporosis was 31.8%\/13.6% (lumbar spine), 57.9%\/10.5% (total hip), 42.1%\/15.8% (femoral neck), and 36.4%\/9.1% (lumbar spine), 44.4%\/0% (total hip) and 55.6%\/0% (femoral neck) at Week 104, respectively. In premenopausal women and men &lt;\u200950\u2009years of age (Z-score), the proportion of patients having BMD below the expected range for age at baseline and Week 104 were 25.0%\/21.2% (lumbar spine), 11.3%\/17.8% (total hip), and 9.9%\/8.9% (femoral neck). In relation to mSASSS change scores \u22652 over 2\u2009years, the increase in lumbar spine BMD was not related to radiographic progression and syndesmophyte formation. No significant changes were observed in the bone turnover markers over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The high proportion of AS patients with diminished BMD was confirmed in this study. An increase of BMD in the lumbar spine after 2\u2009years of secukinumab treatment in patients with AS was found that was probably unrelated to radiographic progression. No relevant effects of secukinumab on bone turnover biomarkers were documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>MEASURE 1 (post hoc analysis) Clinicaltrials.gov,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01358175\">NCT01358175<\/jats:ext-link>; Registered, 23 May 2011.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-021-04930-1","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:03:52Z","timestamp":1639407832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Buehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Haemmerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"issue":"9570","key":"4930_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390.","journal-title":"Lancet."},{"issue":"10089","key":"4930_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet."},{"issue":"1","key":"4930_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4930_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/BOR.0b013e3283620777","volume":"25","author":"N Davey-Ranasinghe","year":"2013","unstructured":"Davey-Ranasinghe N, Deodhar A. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2013;25(4):509\u201316.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"4930_CR5","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/ar3833","volume":"14","author":"E Klingberg","year":"2012","unstructured":"Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4930_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","volume":"38","author":"RJ Lories","year":"2012","unstructured":"Lories RJ, Schett G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin N Am. 2012;38(3):555\u201367.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"4930_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/BOR.0000000000000179","volume":"27","author":"S Tan","year":"2015","unstructured":"Tan S, Wang RS, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol. 2015;27(4):326\u201332.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"4930_CR8","first-page":"2832","volume":"7","author":"HJ Singh","year":"2013","unstructured":"Singh HJ, Nimarpreet K, Ashima DS, Kumar A, Prakash S. Study of bone mineral density in patients with ankylosing spondylitis. J Clin Diagn Res. 2013;7(12):2832\u20135.","journal-title":"J Clin Diagn Res"},{"issue":"1","key":"4930_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12891-017-1718-7","volume":"18","author":"S Malochet-Guinamand","year":"2017","unstructured":"Malochet-Guinamand S, Pereira B, Tatar Z, Tournadre A, Molto A, Dougados M, et al. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskelet Disord. 2017;18(1):357.","journal-title":"BMC Musculoskelet Disord"},{"issue":"15","key":"4930_CR10","first-page":"2740","volume":"127","author":"MA Ulu","year":"2014","unstructured":"Ulu MA, Batmaz I, Dilek B, Cevik R. Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis. Chin Med J. 2014;127(15):2740\u20137.","journal-title":"Chin Med J"},{"issue":"8","key":"4930_CR11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/jbmr.2217","volume":"29","author":"J Munoz-Ortego","year":"2014","unstructured":"Munoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK, et al. Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res. 2014;29(8):1770\u20136.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4930_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40674-016-0055-6","volume":"2","author":"AM Hinze","year":"2016","unstructured":"Hinze AM, Louie GH. Osteoporosis Management in Ankylosing Spondylitis. Curr Treatm Opt Rheumatol. 2016;2(4):271\u201382.","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"5","key":"4930_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11926-010-0122-1","volume":"12","author":"M Magrey","year":"2010","unstructured":"Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep. 2010;12(5):332\u20136.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"4930_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3899\/jrheum.131199","volume":"41","author":"E Klingberg","year":"2014","unstructured":"Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol. 2014;41(7):1349\u201356.","journal-title":"J Rheumatol"},{"issue":"6","key":"4930_CR15","doi-asserted-by":"publisher","first-page":"R179","DOI":"10.1186\/ar4368","volume":"15","author":"E Klingberg","year":"2013","unstructured":"Klingberg E, Lorentzon M, Gothlin J, Mellstrom D, Geijer M, Ohlsson C, et al. Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. Arthritis Res Ther. 2013;15(6):R179.","journal-title":"Arthritis Res Ther."},{"key":"4930_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18.","journal-title":"Biomark Res"},{"issue":"6","key":"4930_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4103\/2230-8210.192914","volume":"20","author":"S Shetty","year":"2016","unstructured":"Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016;20(6):846\u201352.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"4930_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4930_CR19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"4930_CR20","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4930_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177231","volume":"12","author":"F Maas","year":"2017","unstructured":"Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PLoS One. 2017;12(6):e0177231.","journal-title":"PLoS One"},{"issue":"8","key":"4930_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3899\/jrheum.150019","volume":"42","author":"H Li","year":"2015","unstructured":"Li H, Li Q, Chen X, Ji C, Gu J. Anti-tumor necrosis factor therapy increased spine and femoral neck bone mineral density of patients with active ankylosing spondylitis with low bone mineral density. J Rheumatol. 2015;42(8):1413\u20137.","journal-title":"J Rheumatol"},{"issue":"4","key":"4930_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3899\/jrheum.150857","volume":"43","author":"MA van der Weijden","year":"2016","unstructured":"van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE. Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol. 2016;43(4):758\u201364.","journal-title":"J Rheumatol"},{"issue":"2","key":"4930_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2014.05.008","volume":"44","author":"NN Haroon","year":"2014","unstructured":"Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):155\u201361.","journal-title":"Semin Arthritis Rheum"},{"issue":"26","key":"4930_CR25","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"4930_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005.","journal-title":"RMD Open"},{"issue":"2","key":"4930_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4930_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4930_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2019;58(5):859\u201368.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4930_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4930_CR31","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"key":"4930_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.","journal-title":"BMC Med"},{"issue":"5A","key":"4930_CR33","first-page":"1S","volume":"95","author":"Consensus Development Conference on Osteoporosis","year":"1993","unstructured":"Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993. Am J Med. 1993;95(5A):1S\u201378S.","journal-title":"Am J Med"},{"issue":"10169","key":"4930_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364\u201376.","journal-title":"Lancet"},{"issue":"6","key":"4930_CR35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","volume":"43","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115\u201321.","journal-title":"Bone."},{"issue":"1","key":"4930_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4930_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/key128","volume":"58","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landew\u00e9 R, Richards HB, et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford). 2019;58(3):388\u2013400.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4930_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13075-018-1731-8","volume":"20","author":"HR Kim","year":"2018","unstructured":"Kim HR, Hong YS, Park S-H, Ju JH, Kang KY. Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis. Arthritis Res Ther. 2018;20(1):231.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"4930_CR39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/ard.2006.066415","volume":"66","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4930_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10067-012-2018-0","volume":"31","author":"MA van der Weijden","year":"2012","unstructured":"van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31(11):1529\u201335.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4930_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1756-185X.2012.01729.x","volume":"15","author":"SG Lee","year":"2012","unstructured":"Lee SG, Park YE, Park SH, Kim TK, Choi HJ, Lee SJ, et al. Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis. Int J Rheum Dis. 2012;15(3):289\u201396.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"4930_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(2):175\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4930_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-019-0818-9","volume":"21","author":"D Ashany","year":"2019","unstructured":"Ashany D, Stein EM, Goto R, Goodman SM. The effect of TNF inhibition on bone density and fracture risk and of IL17 inhibition on radiographic progression and bone density in patients with axial spondyloarthritis: a systematic literature review. Curr Rheumatol Rep. 2019;21(5):20.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"4930_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13075-017-1480-0","volume":"19","author":"A Deminger","year":"2017","unstructured":"Deminger A, Klingberg E, Lorentzon M, Geijer M, Gothlin J, Hedberg M, et al. Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther. 2017;19(1):273.","journal-title":"Arthritis Res Ther."},{"key":"4930_CR45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/bonekey.2015.35","volume":"4","author":"A Ferreira","year":"2015","unstructured":"Ferreira A, Alho I, Casimiro S, Costa L. Bone remodeling markers and bone metastases: from cancer research to clinical implications. Bonekey Rep. 2015;4:668.","journal-title":"Bonekey Rep"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04930-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04930-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04930-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:11:46Z","timestamp":1699924306000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04930-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["4930"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04930-1","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical studies were conducted in compliance with the Declaration of Helsinki, International Council for Harmonization Guidelines for Good Clinical Practice and local country regulations and were approved by the institutional review board or independent ethics committee (Supplementary Table) at each participating centre. All patients provided written informed consent to participate in the respective studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB: Grant\/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly consultant for: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, Eli Lilly and received speakers bureau fees from: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB pharma, Eli Lilly.BB: Grant\/research support from: Kinemed, Extendicare Foundation, Lilly, GE\/Lunar and MSD; consultant for: GE\/Lunar, Gilead, Theramex, UCB; received speakers bureau fees from UCB, MSD, Biogen, Sanofi Genzyme; Travel support from Janssen, UCB, Gilead, AbbVie.XB: Grant\/research support from: AbbVie, Novartis, Consultant for: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB.LSG: Grant\/research support from: Novartis, Pfizer and UCB, Consultant for: AbbVie, Eli Lilly, GSK, Novartis and UCB.BP: Employee of Novartis and owns Novartis stock.EQF: Employee of Novartis and owns Novartis stock.SH: Employee of Novartis and owns Novartis stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1037"}}